COMPANY INFO
   CORPORATE OVERVIEW
   MANAGEMENT TEAM
   INVESTOR RELATIONS
   HISTORY
   CAREERS
   CONTACT US
 

CAN WE HELP YOU WITH:
   MONITORING / TELEMETRY
   CARDIAC CARE
   OPHTHALMOLOGY
 

Dr. Dagan is a long time veteran in biomedical technology. He is involved in fund raising and strategy consulting to Bio-Medical, Bio-Technology companies and on the Board or in operating responsibilities of several start-ups.

Dr. Dagan has a track record in bio-medical technology development, research and instrumentation.

Dr. Dagan founded Heart-Guard, Inc., a cardiac monitoring service company established in 1989 which grew within 3 years to a telemetry services company for over 2000 physicians in 20 states in the U.S. Founded as a joint venture with W.R. Grace, Dr. established Bergen Medical Imaging Center (BMI), a free standing diagnostic testing facility - one of the largest IDTF facilities in the NY tri-state area providing testing services in nuclear medicine, bone testing and ultrasonography to over 600 physicians and their patients. In 1997 BMI purchased ownership shares from W.R. Grace  

Dr. Dagan served as president for Biofield Corp.- a medical technology company that has been engaged in research and development associated with breast cancer diagnosis since 1990. The company develops unique non invasive detection devices for breast cancer. Research to date supports the potential application of Biofield Corp.'s patented core technology for use in the diagnosis of other epithelial cancers, such as cancer of the ovaries, skin, prostate, and colon, etc.

From 1981 to 1988 Dr. Dagan served as Director of research and development at Laser Industries - a medical lasers manufacturer. He later headed the marketing activities of the company at its U.S. headquarters in Allendale, NJ.

Dr. Dagan started the Biomedical engineering Department at the Sheba Medical Center, Tel-Hashomer in Israel and headed the department from 1975 to 1981 and also served as consultant on medical technologies to the Minister of Health of Israel.

Dr. Dagan served in various advisory capacities on regulatory affairs issues for healthcare companies such as Cardiac Telecom, Inc., Telemedicine General, Inc., American Blood Bank, Inc., E&C Medical, Inc., Yesum-Hebrew University. Dr. Dagan has extensive knowledge and experience with device safety clearance and clinical trials for FDA as well as CMS coverage & reimbursement issues for medicare coverage of new technologies.

As a consultant in Biomedical engineering Dr. Dagan served as adviser to Elscint, in the development of their Computerized Gamma Cameras and consultant to Beth Israel Medical Center and The Bronx VA Hospital in Imaging and Radiology.

Dr. Dagan holds a Ph.D. in Science and Engineering from Columbia University, New York on "The development of the Nuclear Imaging methodology in Cardiology"; M.Sc. from the Technion/Israel Institute of Technology, ITT in Nuclear Sciences on "Development of a system for measuring thermal neutron energies"; B.Sc in Mechanical Engineering and Nuclear Sciences from the Technion, ITT.

Kevin Sharkey
Director Sales

Mr. Sharkey has worked in pharmaceutical & medical device sales for over 20 years. His specialized knowledge is in the fields of Ophthalmology, Dermatology and Cardiology.

Prior to joing MSO, Mr. Sharkey worked at Alcon, Galderma and Bausch & Lomb in various field positions; ultimately as district sales manage and national sales manager for Galderma S.A.

Mr. Sharkey is a qualified hematology technician.

Tiran Dagan , 6FootMedia
Strategic Alliances

Mr. Dagan, founder of New York based technology consulting firm 6FootMedia advises MSO on new technology opportunities and the implementation and deployment of marketing and regulatory compliance matters.

Mr. Dagan launched the operational end of the medical startups that MSO has embarked upon. With over 15 years of experience in information technology, Mr. Dagan led some of MSO's companies to the development of software solutions. These developments were later licensed and embedded into diagnostic equipment by Siemens, Hitachi and Toshiba. The developments are in the fields of telemedicine, internet based patient information systems and standardized protocols (DICOM, HL7).

Mr. Dagan developed several public policy plans which combine his experience in medical informatics and medical diagnostic testing such as target outcome capitation.

Mr. Dagan has published articles in information technology issues such programming, informatics, multimedia and animation. His articles were translated to several languages and published around the globe. He authored and developed original multimedia software and components for web, video and print.

Mr. Dagan holds an MBA in International Business from Tel-Aviv University/Wharton Program and a B.Sc in Computer Sciences in Artificial Intelligence from state university of New York.

Debbie Yannete
Medical Billing Manager

George Livne
Product Engineer

Ron Bar-Nadav, Esq.
Regulatory & Compliance

Emma Butin, Esq.
Legal Affairs

Mr. Fuhrman, the Chairman of Fuhrman Associates, Inc. for over twenty-five years, has served a wide variety of client companies ranging from Fortune 500 corporations to more modest sized businesses and start-up situations, with an emphasis on consumer products. During this period, he has also served from time to time in executive positions to implement recommendations for various clients. Mr. Fuhrman has an MBA from the Harvard Business School where he was offered a faculty position on graduation.

Mr. Fuhrman founded and served as CEO of Eggland's Best Inc. from 1988-95 developing the first premium quality, patented and advertised hen's egg. He financed the company primarily through the sale of $6 Million worth of franchises to egg producers. Although introduced in 1993, in only 60% of the country, at about twice the price of ordinary eggs, Eggland's Best was the biggest volume new food brand introduced that year, achieving sales of $32 Million (wholesale dollars) and generating $2 Million in profits to Egglands Best, Inc. Sales in 2003 will exceed $50 Million.

In 1975, Mr. Fuhrman conceived and developed "Naturally Good" baby food (no salt, no sugar, no additives) for Beech-Nut and agreed to serve as Marketing Vice President from 1975-77 to implement the program. He was also named President of Beech-Nut-Milupa, a joint venture with Milupa AG of Germany. The program reversed a 15 year decline in Beech-Nut sales, increased profit margins and enabled private owners to sell to Nestle at a substantial gain.

Repositioned and created US advertising program for Ricola Swiss herb products after brand had been sold in U.S. for over 20 years without ever exceeding $300,000 in annual sales. New program initiated in 1984 increased yearly sales to over $7 Million within three years. Annual sales now exceed $60 Million.

Served as Consultant and Senior Vice President of totes from 1979-81 implementing a new advertising program that increased sales over 20% and operating profits over 100%. By increasing sales in weaker markets over 65%, he broadened the base of business and made company less dependent on weather conditions in a limited number of areas. He also introduced new, non weather sensitive products and expanded the business to Europe.

Prior to establishing Fuhrman Associates Inc., Mr. Fuhrman served as Merchandising Manager of Chesebrough-Pond's and held a number of marketing management positions at Procter & Gamble, including Brand Manager on Crest toothpaste and Director of New Products and Expansion Planning. In the latter position, he initiated projects leading to Head & Shoulders Shampoo, Pampers disposable diapers and other highly profitable brands.

Daniel B. Frier, Esq.

Mr. Frier is senior partner at the law firm Frier & Levit where he practices health care law.

Over the years, Mr. Frier has guided physicians on the laws governing the practice of medicine, contractual arrangements between hospitals and physicians and leases/contracts with third party vendors.

In his capacity as a member of the advisory board, Mr. Frier audits and advises our affiliates with the following issues:

• Hospital/physician negotiations, joint ventures and medical staff issues;
• Forming and advising medical practices, IPAs, PHOs and MSOs;
• Forming and advising ambulatory care centers;
• Negotiations with third-party payors;
• Developing Health care corporate compliance programs;
• Representing hospitals, nursing homes and other institutional clients;
• Federal and State fraud and abuse, anti-kickback and self-referral (e.g., Stark I and II) matters.

Mr. Frier is also the moderator of our discussion board on legal issues in healthcare.

Yoav Millet. Mr. Millet has more than a decade of experience as a venture capitalist and manager of emerging companies in the healthcare field. He is currently the Chief Executive Officer of Titanium Ventures. Prior to founding Titanium Ventures in 2001, he was the Managing Director of Nessuah Zannex Venture Capital Management Ltd. He also serves as the Managing Director of Mezam Capital Fund Management Ltd., which is the General Partner of the AG-Tech Fund (a $25 million venture fund dedicated to healthcare investments). In parallel to his management of the AG-Tech Fund, Mr. Millet has served as Chairman and Chief Executive Officer of two of that fund’s portfolio companies (MCM Environmental Technologies Inc and NeuroVision Inc).

Prior to heading the AG-Tech Fund, Mr. Millet co-headed the investment-banking activities of Zannex Group (formerly Clali & Associates Financial Management) from 1992 to 1997. Prior to becoming a venture capitalist, Mr. Millet was actively involved in the management of two institutional investment companies and led a broad range of transactions for emerging growth companies including mergers and acquisitions, corporate partner agreements, public offerings, and private placements of equity and debt. Prior to joining the Zannex Group in 1992 Mr. Millet was an internal bank auditor with Israel General Bank (LCF Edmond De Rothschild) and a manager at two public accounting firms.

Mr. Millet is a CPA and holds dual Bachelor degrees in Accounting and Economics earned at Tel Aviv University.

Dr. Avi Livnat

Founder and Managing Director of Novia Pharmaceuticals Ltd., a new, private, Israeli drugs' development company which has entered a Research and License agreement with Tel Aviv and Jerusalem University, to develop novel pharmaceutical antioxidants for treatment of neurodegenerative diseases. Novia, together with PharmaBio/Quintiles Transnational (the lead investor in Novia) have been awarded a BIRD Foundation grant for their joint project (2001- present).

Founder and General Manager of Quintiles Israel Ltd., a wholly owned subsidiary of Quintiles Transnational Inc., the world largest Contract Research Organization. Under his management and during three years Quintiles Israel grew to 60 employees, to become the largest company of its kind in Israel. It currently offers a variety of services to the biomedical industry: strategic and regulatory consulting, pre-clinical testing, clinical trials design and management and pharmaco-economics evaluations

Dr. Livnat founded the Medical Device Department at the Ministry of Health of the State of Israel and was its head for four years. His department performs a similar role to the U.S. Food & Drug Administration Administration. It practices as the safeguard of Safety and Efficacy of Medical Device (FDA-CDRH); Modernizing the Pharmaceutical Administration; Establishing international connections and cooperative working relationship with the FDA, Canadian and European authorities. Modernizing the Clinical Trials regulatory system in Israel.

From 1988 to 1991 Dr. Livnat was a senior consultant to IBM Corporation in New York in the design and marketing of large-scale computer systems at financial and institutions.

Previously, Dr. Livnat served as a Professor of Physiology and Biophysics at the University of Illinois at Urbana-Champaign. He holds a B.Sc. from the Hebrew University of Jerusalem in Physics and Mathematics, a Ph.D. from the University of Southern California in Cardiovascular Physiology and Biomedical Engineering and a M.Sc. from the University of Illinois in Economics.